Literature DB >> 14537110

2-Deoxy-2-[18F]fluoro-D-glucose positron emission tomography uptake in a giant adrenal myelolipoma.

Vinicius Ludwig1, Michael H Rice, William H Martin, Mark C Kelley, Dominique Delbeke.   

Abstract

Incidental adrenal lesions found on anatomic imaging are not uncommon. 2-Deoxy-2-[18F]fluoro-D-glucose positron emission tomography (FDG-PET) imaging is highly accurate in the differentiation of benign from malignant adrenal lesions, both in patients with proven malignancy and with adrenal lesions detected incidentally. A 60-year-old white female with a history of lower mid-back pain underwent computerized tomography (CT) imaging that identified a 15-cm complex mass within the left adrenal gland with soft tissue, cystic, and adipose components. FDG-PET imaging showed significant hypermetabolic activity within portions of the mass with central photopenia suggesting a malignant lesion with central necrosis. Surgical excision and pathological examination, however, revealed a benign adrenal myelolipoma with extensive adenomatous and hematopoietic elements. Prior reports of adrenal myelolipoma evaluated with FDG-PET imaging have described no significant FDG uptake within these benign tumors. This case is an unusual example of histologically proven benign adrenal myelolipoma that was hypermetabolic on FDG-PET imaging. Correlation of pathologic and imaging findings demonstrated that the hypodense regions on CT were hypometabolic on FDG-PET and corresponded to cystic necrosis and adipose elements, whereas the adenomatous and hematopoietic elements were hypermetabolic.

Entities:  

Year:  2002        PMID: 14537110     DOI: 10.1016/s1536-1632(02)00018-5

Source DB:  PubMed          Journal:  Mol Imaging Biol        ISSN: 1536-1632            Impact factor:   3.488


  8 in total

Review 1.  Recent advances in the imaging of adrenal and neuroendocrine tumours.

Authors:  Priya Narayanan; Rodney Reznek
Journal:  Clin Med (Lond)       Date:  2009-08       Impact factor: 2.659

Review 2.  Adrenal myelolipoma: a comprehensive review.

Authors:  Ábel Decmann; Pál Perge; Miklós Tóth; Peter Igaz
Journal:  Endocrine       Date:  2017-11-21       Impact factor: 3.633

3.  FDG-PET/CT and FLT-PET/CT for differentiating between lipid-poor benign and malignant adrenal tumours.

Authors:  Masatoyo Nakajo; Megumi Jinguji; Yoshihiko Fukukura; Yoriko Kajiya; Atushi Tani; Masayuki Nakajo; Yoshiaki Nakabeppu; Hiroshi Arimura; Yoshihiko Nishio; Fumihiko Nakamura; Takashi Yoshiura
Journal:  Eur Radiol       Date:  2015-04-30       Impact factor: 5.315

Review 4.  Metabolic and anatomic characteristics of benign and malignant adrenal masses on positron emission tomography/computed tomography: a review of literature.

Authors:  Asha Kandathil; Ka Kit Wong; Daniel J Wale; Maria Chiara Zatelli; Anna Margherita Maffione; Milton D Gross; Domenico Rubello
Journal:  Endocrine       Date:  2014-10-02       Impact factor: 3.633

5.  Adrenal morphology and associated comorbidities in congenital adrenal hyperplasia.

Authors:  Diala El-Maouche; Fady Hannah-Shmouni; Ashwini Mallappa; Courtney J Hargreaves; Nilo A Avila; Deborah P Merke
Journal:  Clin Endocrinol (Oxf)       Date:  2019-05-07       Impact factor: 3.478

6.  Appearance of Adrenal Myelolipomas on 2-deoxy-2-(18F) fluoro-D-glucose Positron Emission Tomography-Computed Tomography.

Authors:  Steven P Rowe; Mehrbod S Javadi; Lilja B Solnes; Elliot K Fishman
Journal:  World J Nucl Med       Date:  2017 Oct-Dec

Review 7.  Adrenal Mass Characterization in the Era of Quantitative Imaging: State of the Art.

Authors:  Maxime Barat; Anne-Ségolène Cottereau; Sébastien Gaujoux; Florence Tenenbaum; Mathilde Sibony; Jérôme Bertherat; Rossella Libé; Martin Gaillard; Anne Jouinot; Guillaume Assié; Christine Hoeffel; Philippe Soyer; Anthony Dohan
Journal:  Cancers (Basel)       Date:  2022-01-23       Impact factor: 6.639

Review 8.  Myelolipomas and other fatty tumours of the adrenals.

Authors:  Nazih Khater; Raja Khauli
Journal:  Arab J Urol       Date:  2011-11-21
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.